Biogen stops Phase II for returned IPF candidate

Seven years after regaining rights to BG00011 (STX-100), Biogen terminated its Phase II trial of the mAb for idiopathic pulmonary fibrosis (IPF) due to safety concerns.

Biogen

Read the full 262 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE